Skip to content

BC Cancer researchers develop an improved hereditary cancer test

The research is published in Cell Genomics
31383328_web1_221229-TDT-Cancer-research_1
“All of our chromosomes have marks that are indicative of whether the chromosome came from our mother or our father,” explains Dr. Louis Lefebvre, associate professor of medical genetics at UBC and co-author of the paper. “The challenge is that over the three billion base pairs that represent our genome, only approximately 190 tiny regions contain these parental marks.” Photo: Unsplash

Just before Christmas, researchers at the BC Cancer Research Institute announced they had made an advancement in genetic testing that allows for more accurate prediction of which parent’s genes led to an individual’s increased cancer risk.

Researchers say this improves the efficiency of familial testing strategies and could eliminate concern for patients at high risk of cancer caused by genes inherited from a parent.

The approach was spearheaded by Vahid Akbari and Dr. Steven Jones at Canada’s Michael Smith Genome Sciences Centre (GSC) at BC Cancer, and by Vincent Hanlon and Dr. Peter Lansdorp at the BC Cancer Research Institute’s Terry Fox Laboratory. The new test confirms whether a cancer predisposing gene variant is present in a patient, and can determine whether the variant was inherited from the mother or the father — an understanding that was not possible until now.

“Being able to assign the parent of origin to cancer variants allows us to rapidly identify other family members who may be at risk,” says Dr. Kasmintan Schrader, co-medical director of the Provincial Hereditary Cancer Program at BC Cancer, assistant professor of medical genetics at the University of British Columbia (UBC) and a co-author of the study. “Allowing us to focus on one side of the family will help save lives by concentrating on prevention efforts. This new approach will eliminate the unnecessary psychological burden of needing to test family members on the other side who are not at an increased risk, reduce the need for clinical counselling and focus resources on identifying and supporting those truly at risk.”

“The approach has been enabled by new long-read sequencing technology which can sequence not only DNA but also determine subtle functional alterations to DNA,” said Dr. Jones.

Unlike other DNA sequencing approaches, this approach uses thousands of microscopically small pores to determine the sequence of DNA as it travels through them.

“All of our chromosomes have marks that are indicative of whether the chromosome came from our mother or our father,” says Dr. Louis Lefebvre, associate professor of medical genetics at UBC and co-author of the paper. “The challenge is that over the three billion base pairs that represent our genome, only approximately 190 tiny regions contain these parental marks.” Technology developed by Dr. Lansdorp provided the final missing piece, allowing these tiny regions to be linked to entire chromosomes.

For certain patients the promise of this test might be more profound. Those bearing damaging variants of certain genes are at very high risk of developing certain cancers over their lifetime, but only if the defective gene is inherited from their father. If it is inherited from the mother, the patient has no increased risk. For those at risk, they face a lifetime of regular screening and testing to identify tumours early. For some individuals with the variant, though, family members are not around to help identify from which parent the variant was inherited. For half of the approximately 300 patients in Canada in this position and many more around the world, this new test could eliminate a lifetime of unnecessary hospital visits and the psychological burden of increased cancer risk.

The research is published in Cell Genomics.

Quick Facts:

· The Hereditary Cancer Program provides genetic counselling and genetic testing for BC/Yukon residents who may have inherited an increased risk for specific types of cancer.

· Hereditary cancer is not common. Less than 10 per cent of all cancer is hereditary.

· Self-referrals to the Hereditary Cancer Program are accepted if a relative has shared details about their hereditary cancer gene mutation or if you are concerned about cancer in your family and do not currently have a family doctor or nurse practitioner.

· As a research institute at UBC and PHSA, the BC Cancer Research Institute (BCCRI) is as a hub for cancer research activity across the province, advancing cancer research discoveries and transformational technologies and treatments.

Learn More:

· www.bccancer.bc.ca/our-services/services/hereditary-cancer

· www.bcgsc.ca

BC Cancer, a program of the Provincial Health Services Authority, is committed to reducing the incidence of cancer, reducing the mortality from cancer and improving the quality of life of those living with cancer. It provides a comprehensive cancer control program for the people of British Columbia by working with community partners to deliver a range of oncology services, including prevention, early detection, diagnosis and treatment, research, education, supportive care, rehabilitation and palliative care. For more information, visit www.bccancer.bc.ca or follow us on Twitter @BCCancer.

Ranked among the world’s top medical schools with the fifth-largest MD enrollment in North America, the UBC Faculty of Medicine is a global leader in both the science and the practice of medicine. Guided by our vision—to transform health for everyone—our faculty, learners, staff and alumni are accelerating discovery and creating pathways to better health for Canada and beyond. Through collaboration with our partners, we strive to meet the demands of today and tomorrow, bringing real and lasting hope to people everywhere. For more information, visit med.ubc.ca or follow us on Twitter @UBCmedicine.



Sheri Regnier

About the Author: Sheri Regnier

Read more